Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

NCT07286929 | Recruiting DMC

• 1 other identifier: neGLIO
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from other deficits. This study aims to evaluate the extent and variation over time of visuo-spatial deficits in patients undergoing surgical removal of parietal lobe gliomas. This will help characterize the cognitive profile of these patients to identify personalized treatment and rehabilitation paths.

Conditions

Glioma; Parietal Lobe Glioma; Visuspatial Deficit; Unilateral Spatial Neglect (USN)

Keywords

Visuospatial deficit; Glioma; Parietal Lobe; Neuropsychological assessment; Hemineglect

Outcome Measures

Primary Outcomes (1)

• Change in Visuospatial Deficit Prevalence

  Prevalence of patients with a score below the cut-off in specific neuropsychological tests for visuo-spatial aspects (Line Bisection, Bell/Letter Cancellation, Apple Cancellation, Fluff Test) and the extent of change compared to baseline.

  Baseline (pre-surgery), 3-4 months post-surgery, 6 months post-surgery.

Secondary Outcomes (4)

• Association with Radiological Data

  Up to 6 months post-surgery

• Association with Clinical-Demographic Data

  Up to 6 months post-surgery.

• Association with Performance Status

  Time Frame: Up to 6 months post-surgery.

• Association with Histological/Molecular Data

  Up to 6 months post-surgery.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with suspected parietal lobe glioma

You may qualify if:

• Patients \>18 years old
• Patients must understand the Italian Language
• Patients with suspected parietal lobe glioma

You may not qualify if:

• Tumor site other than parietal lobe.
• Patients who cannot undergo surgical resection (stereotactic/open biopsy).
• Patients who received a previous chemotherapy and/or radiotherapy treatment.
• Patients with a history of intracranial mass lesion or traumatic brain injury.
• Patients with a history of other CNS diseases (e.g., stroke, metastasis).
• Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).

Sponsors & Collaborators

• Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta: lead

Study Sites (1)

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

RECRUITING

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Francesco Di Meco, MD

  Fondazione IRCCS Istituto Neurologico Carlo Besta

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Francesco Di Meco, MD

CONTACT

+ 39 02.2394; francesco.dimeco@istituto-besta.it

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 3, 2025
• First Posted: December 16, 2025
• Study Start: December 3, 2024
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: December 16, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)